Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.

Fujimaki, Shun

Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. [electronic resource] - Cancer letters Jun 2012 - 98-108 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1872-7980

10.1016/j.canlet.2011.12.043 doi


Antineoplastic Agents--therapeutic use
Ataxia Telangiectasia Mutated Proteins
Benzenesulfonates--therapeutic use
Caffeine
Carcinoma, Hepatocellular--drug therapy
Cell Cycle Proteins--antagonists & inhibitors
Cell Line, Tumor
DNA-Binding Proteins--antagonists & inhibitors
Drug Screening Assays, Antitumor
Drug Synergism
Humans
Liver Neoplasms--drug therapy
Niacinamide--analogs & derivatives
Phenylurea Compounds
Protein Serine-Threonine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins c-akt--metabolism
Pyridines--therapeutic use
RNA, Small Interfering
Signal Transduction--drug effects
Sorafenib
Tumor Suppressor Proteins--antagonists & inhibitors